Dietary Vitamin B3 Deprivation Drives Multi-System Physical Decline and Frailty in Mice

A Utah State University-led study of chronic NAD deficiency in mice was published in Nature Communications on September 23, 2026. The university reported the findings on October 26, 2026.

According to the university, genetically engineered mice deprived of dietary vitamin B3 developed chronic NAD deficiency alongside changes across several body systems and a shorter lifespan than mice receiving vitamin B3. Restoring vitamin B3 improved several measures, including partial recovery of bone structure. The central finding concerns how sustained NAD deficiency affects an organism and which consequences respond when the deficiency is corrected.

Evidence setting: Animal models, specifically genetically engineered mice.

Following NAD Loss

USU describes NAD as a molecule involved in cellular energy metabolism and signaling. Its account also identifies roles in DNA repair and gene expression, as well as inflammation regulation. Those functions provide a biological reason to look across several kinds of outcomes rather than focusing on a single visible symptom.

These roles are the starting point for interpreting the experiment. The researchers created a sustained shortage and followed the resulting changes across the body. The logic is to connect a defined biological disturbance with the physical and biological responses that accompany it.

A controlled deficiency

The team used acquired niacin dependency mice, known as ANDY mice. According to USU, these animals are genetically engineered to require vitamin B3 in their diet. Withholding that vitamin allowed the researchers to induce chronic NAD deficiency.

The comparison group consisted of ANDY mice receiving vitamin B3. This makes the dietary condition central to reading the results: the reported differences were between mice with the same engineered dependency but different access to the required nutrient. The experiment therefore gave the researchers a controlled way to investigate sustained NAD loss.

USU researchers worked with collaborators at the Mayo Clinic's Kogod Center on Aging and other institutions. Andres Benitez-Rosendo and Morgan Feuz were the shared first authors. USU says the work spanned more than six years and describes a 21-week period for the bone-imaging work.

The project duration and the bone-imaging period describe different aspects of the research. Keeping those timelines separate helps readers understand what was being followed without treating the full research effort as a single animal follow-up period.

A multi-system response

In mice of both sexes, USU reported reduced bone mass and reductions in lean and fat mass. The animals also had impaired exercise capacity and frailty. Other reported changes included fur browning and a hunched back, along with cataracts. Shortened lifespan was part of the reported pattern.

Together, these findings describe more than a change in appearance. Body composition and exercise capacity concern different aspects of physical condition. Survival adds a separate outcome. Reading them individually gives a clearer account of the experiment than compressing every result into a single claim about aging.

The functional measures are especially relevant to the study's healthy-aging context. Exercise capacity and frailty address how the animals were functioning, while the lifespan result addresses survival. Those are related questions, but they require their own measurements and interpretations.

This multi-system view also connects with broader context on how body systems age together. In this experiment, the pattern across tissues and functions is the feature that makes chronic NAD deficiency an interesting subject for aging research.

Recovery after restoration

USU reports that several physical and biological measures improved after vitamin B3 was restored. Bone structure showed partial recovery. The restoration phase adds a useful comparison to the deficiency phase by asking which outcomes respond when the model's dietary requirement is met again.

Partial recovery is a specific description of the bone result. It keeps attention on the tissue that was assessed and the degree of recovery the university reported. The broader improvements matter because the researchers were examining a collection of physical and biological outcomes rather than a single measurement.

From an experimental perspective, depletion and restoration answer complementary questions. The first examines the consequences of a chronic shortage. The second examines responsiveness after that shortage is addressed. That approach offers a concrete entry point into the relationship between aging biology and healthy function.

Evidence Boundaries

• An engineered deficiency model. The animals were made dependent on dietary vitamin B3 and then deprived of it. This is a targeted experimental disturbance rather than a direct representation of ordinary human aging. Its value is in testing consequences of chronic deficiency within that model.
• Biological roles are not pathway proof. NAD's involvement in energy metabolism and DNA repair provides a rationale for the experiment. Those roles alone do not establish which process produced each reported physical change. The mechanistic reading should stay tied to direct evidence for a pathway rather than assigning every outcome to one of the molecule's known functions.
• A limited explanation of aging. Feuz said low NAD alone does not explain aging in its entirety. He described overlap with some aspects of aging as a basis for hypotheses. The useful interpretation is that the model identifies questions worth investigating, not a single cause for every age-related change.
• Outcome-specific recovery. The bone finding was partial recovery after vitamin B3 restoration. Improvement in particular measures should be read at that level, rather than renamed as reversal of the aging process. Restoring a missing dietary input and improving normal aging are different experimental questions.
• Incomplete public reporting. The USU article does not provide sample sizes, a lifespan effect size or a detailed limitations section. Readers therefore cannot judge the magnitude of the survival difference or fully assess the design from that account alone. No numerical lifespan gain or loss should be inferred.
• No human supplement test. The mouse study did not test an NAD-boosting supplement in people. Its shortened-lifespan finding does not establish that raising NAD extends human lifespan or healthspan. Human intervention evidence needs to be assessed separately rather than borrowed from the animal result.
• Unresolved safety and effectiveness. Corresponding author Mirella Meyer-Ficca described NAD-boosting supplements as an area for future research. In USU's account, she placed that work within the broader goal of understanding aging to support healthy and independent lives. Safety and effectiveness remain questions for that research.

For a separate human comparison, Nutraceuticals World reported a 2026 randomized, placebo-controlled trial of NMN involving 62 healthy adults aged 65 or older. The intervention lasted 24 weeks. This is a different evidence category: a supplement trial in people rather than a deficiency experiment in mice.

That distinction gives readers a practical way to assess a claim. First identify the study population and the intervention. Then check whether the measured outcome matches the promised benefit. A molecular finding, a physical function result and a survival result each answer a different question.

An NAD-related product claim should therefore be evaluated against relevant human evidence on the specific outcome being advertised. The presence of a plausible biological story is a reason to ask for that evidence. Personal decisions about supplements are best discussed with a qualified health care professional.

The Next Test

The next step is replication beyond the engineered deficiency model, followed by human studies that directly assess safety and meaningful health outcomes for specific NAD-related interventions.

How AgeAmaze helps

A deliberately induced NAD shortage is useful for studying biology but creates a translation problem when the discussion shifts to people. AgeAmaze makes the distinction between animal experiments and human evidence easier to follow for adults weighing longevity claims, with readable explanations of the mechanisms and the uncertainty surrounding emerging interventions.

Read the research

Sources

1. USU Researchers Reveal How Single Molecule Unlocks Secrets of Aging
2. NMN Sustainably Raises NAD+ in Older Adults: Study